Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
34,723,329
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
21,774,197
-
Shares change
-
+4,303,470
-
Total reported value, excl. options
-
$200,973,364
-
Value change
-
+$34,080,625
-
Put/Call ratio
-
81.36%
-
Number of buys
-
55
-
Number of sells
-
-30
-
Price
-
$9.23
Significant Holders of IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) as of Q2 2023
97 filings reported holding IGMS - IGM Biosciences, Inc. - Common Stock, par value $0.01 per share as of Q2 2023.
IGM Biosciences, Inc. - Common Stock, par value $0.01 per share (IGMS) has 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21,774,197 shares
of 34,723,329 outstanding shares and own 62.71% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (3,230,870 shares), BAKER BROS. ADVISORS LP (3,157,210 shares), Redmile Group, LLC (2,971,542 shares), Artal Group S.A. (2,522,244 shares), FMR LLC (2,135,119 shares), MILLENNIUM MANAGEMENT LLC (984,663 shares), RA CAPITAL MANAGEMENT, L.P. (937,500 shares), BlackRock Inc. (857,171 shares), VANGUARD GROUP INC (697,288 shares), and GOLDMAN SACHS GROUP INC (672,189 shares).
This table shows the top 77 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.